Skip Nav Destination
Issues
1 October 2013
-
Cover Image
Cover Image
Current fecal tests (occult blood, methylation, DNA mutations) target minute amounts of tumor products among a large amount of fecal material and thus have suboptimal performance. By exploiting field carcinogenesis as a modality to amplify the neoplastic signal, the present study demonstrates that endoscopically normal rectal brushings have striking nano-architectural alterations which are detectable utilizing a novel optical technique, partial wave spectroscopic microscopy (PWS). Mucus layer fecal colonocytes (MLFCs) at preneoplastic and neoplastic time-points in azoxymethane (AOM)-treated rat models were examined using PWS analysis to derive the nano-architectural parameter, disorder strength (Ld). MLFCs from both control and AOM-treated animals appeared microscopically normal and identical under bright field microscopy. However, superimposing Ld pseudocolor maps on the images (cover micrograph; saline-treatment; AOM treatment not shown) revealed marked differences (elevation) in Ld in the AOM-treated rats in the areas of nucleus and cytoplasm when compared to control animals. Thus, by utilizing a biophotonics proof of principle approach to fecal assay, the present study demonstrates that targeting the nano-architectural changes of field carcinogenesis rather than the detection of tumor products may provide a novel paradigm for colorectal cancer screening. See article by Roy and colleagues (beginning on page 1111) for more information. - PDF Icon PDF LinkTable of Contents
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Commentaries
Research Articles
Liver Fatty Acid-Binding Protein (L-Fabp) Modifies Intestinal Fatty Acid Composition and Adenoma Formation in ApcMin/+ Mice
Sekhar Dharmarajan; Elizabeth P. Newberry; Grace Montenegro; ILKe Nalbantoglu; Victoria R. Davis; Michael J. Clanahan; Valerie Blanc; Yan Xie; Jianyang Luo; James W. Fleshman, Jr.; Susan Kennedy; Nicholas O. Davidson
Anti-Genotoxic Potential of Bilirubin In Vivo: Damage to DNA in Hyperbilirubinemic Human and Animal Models
Marlies Wallner; Nadja Antl; Barbara Rittmannsberger; Stephanie Schreidl; Khatereh Najafi; Elisabeth Müllner; Christine Mölzer; Franziska Ferk; Siegfried Knasmüller; Rodrig Marculescu; Daniel Doberer; Henrik E. Poulsen; Libor Vitek; Andrew C. Bulmer; Karl-Heinz Wagner
High-Fat, High-Calorie Diet Promotes Early Pancreatic Neoplasia in the Conditional KrasG12D Mouse Model
David W. Dawson; Kathleen Hertzer; Aune Moro; Graham Donald; Hui-Hua Chang; Vay Liang Go; Steven J. Pandol; Aurelia Lugea; Anna S. Gukovskaya; Gang Li; Oscar J. Hines; Enrique Rozengurt; Guido Eibl
Risk Factors for Non-initiation of the Human Papillomavirus Vaccine among Adolescent Survivors of Childhood Cancer
James L. Klosky; Kathryn M. Russell; Kristin E. Canavera; Heather L. Gammel; Jason R. Hodges; Rebecca H. Foster; Gilbert R. Parra; Jessica L. Simmons; Daniel M. Green; Melissa M. Hudson
A Double-Blind, Randomized, Neoadjuvant Study of the Tissue Effects of POMx Pills in Men with Prostate Cancer Before Radical Prostatectomy
Stephen J. Freedland; Michael Carducci; Nils Kroeger; Alan Partin; Jian-yu Rao; Yusheng Jin; Susan Kerkoutian; Hong Wu; Yunfeng Li; Patricia Creel; Kelly Mundy; Robin Gurganus; Helen Fedor; Serina A. King; Yanjun Zhang; David Heber; Allan J. Pantuck
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.